INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Zentalis Pharmaceuticals, Inc.; Urges Zentalis Stockholders to Contact Abbott Cooper Regarding Their Legal Rights


STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”) on behalf of the Company’s investors.

The investigation seeks to determine whether Zentalis’ board of directors has violated its fiduciary duty by instituting measures that impermissibly interfere with the ability of Zentalis stockholders to elect directors of their choosing.

Zentalis stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or visiting our website at for additional information about this investigation as well as their legal rights and options.


Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit


Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674

Attorney advertising. Prior results do not guarantee a similar outcome.

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.